Clinical trials are the foundation of medical innovation, but even the most promising studies can face setbacks without proper regulatory support. From protocol deviations to incomplete documentation, compliance challenges can delay approvals, increase costs, and put investor confidence at risk.

When James Carter (name changed), CEO of Medivance Biotech (name changed), set out to launch his company’s first Phase II oncology trial, he knew the science was strong. What he didn’t anticipate was how quickly regulatory hurdles could derail progress.

In today’s clinical research landscape, patient enrollment remains one of the most critical—and challenging—drivers of trial success. For Contract Research Organizations (CROs), the ability to consistently meet enrollment targets is no longer just an operational goal; it is a key differentiator in delivering value to sponsors.

Phase I clinical trials are the first step in testing investigational drugs in humans. These studies are often conducted in specialized Contract Research Organizations (CROs) and usually involve healthy volunteers to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics.